Nearly two months ago, a U.S. bankruptcy court judge approved a controversial Purdue Pharma plan that would funnel billions of dollars to pay for the harm caused by the OxyContin opioid painkiller.
At the core, the deal calls for some members of the Sackler family — which controlled Purdue — to contribute more than $4.3 billion over nearly a decade to compensate individuals, state and local governments, and tribal communities for the cost of the opioid crisis. The deal was in response to some 3,000 lawsuits that prompted the company to seek bankruptcy in 2019. But even though the plan was approved, the money hasn’t started flowing and it remains unclear when that will happen.
Create a display name to comment
This name will appear with your comment